思创医惠科技股份有限公司 2024 年度独立董事述职报告 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在任何影响独立董事独立性 的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关法律法规、 规章制度中关于独立董事独立性的要求。本人对 2024 年独立性情况进行了自查， 并将自查情况提交公司董事会。 二、独立董事年度履职情况 （一）出席会议的情况 （梁立-已离任） 本人作为思创医惠科技股份有限公司（以下简称"公司"）的独立董事，在 2024 年度任职期间，本人严格按照《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《公司章程》《独立董事工作制度》等相关法律、 法规及规范性文件的规定和要求，勤勉尽责、独立谨慎地行使权利，积极出席相 关会议，认真审议董事会各项议案，对公司重点关注事项进行了独立审查。 ...

思创医惠科技股份有限公司 2024 年度独立董事述职报告 （赵合宇-已离任） 本人作为思创医惠科技股份有限公司（以下简称"公司"或"思创医惠"） 的独立董事，在 2024 年度任职期间，本人严格按照《上市公司独立董事管理办 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》《公司章程》《独立董事工作制度》 等相关法律、法规及规范性文件的规定和要求，勤勉尽责、独立谨慎地行使权利， 积极出席相关会议，认真审议董事会各项议案，对公司重点关注事项进行了独立 审查。本人根据公司实际情况，充分发挥自身专业优势，提出了意见和建议，促 进公司规范运作，切实维护了公司和股东尤其是中小股东的利益，充分发挥了独 立董事及相应专门委员会的作用。 现将本人 2024 年度任职期间（2024 年 1 月 1 日至 2024 年 12 月 5 日）履行 独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人赵合宇，男，汉族，1966 年出生，中国国籍，无境外永久居留权，会计 学硕士研究生学历，注册会计师，注册税务师。1991 ...

思创医惠科技股份有限公司 2024 年度独立董事述职报告 （刘银） 本人作为思创医惠科技股份有限公司（以下简称"公司"）的独立董事，在 2024 年度任职期间，本人严格按照《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《公司章程》《独立董事工作制度》等相关法律、 法规及规范性文件的规定和要求，勤勉尽责、独立谨慎地行使权利，积极出席相 关会议，认真审议董事会各项议案，对公司重点关注事项进行了独立审查。本人 根据公司实际情况，充分发挥自身专业优势，提出了意见和建议，促进公司规范 运作，切实维护了公司和股东尤其是中小股东的利益，充分发挥了独立董事及相 应专门委员会的作用。 现将本人 2024 年度履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人刘银，男，汉族，1969 年出生，中国国籍，无境外永久居留权，法学硕 士研究生学历。曾获中国贸易救济研究奖。2003 年 8 月至 2006 年 8 月，任环中 律师事务所律师；2006 年 8 月至 2007 年 7 月， ...

思创医惠科技股份有限公司 董事会关于独立董事独立性自查情况的专项报告 思创医惠科技股份有限公司（以下简称"公司"）董事会根据《上市公司独 立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》及《独立董事工作制度》等相关法律、法规和规章制度的规定 和要求，就公司在任独立董事叶肖剑先生、褚国弟先生、刘银先生的独立性情况 进行评估并出具如下专项意见： 经核查，公司独立董事叶肖剑先生、褚国弟先生、刘银先生已向公司出具《独 立董事独立性自查报告》，上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在任何影响独立董事独立性 的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规章制度中关于 独立董事独立性的要求。 思创医惠科技股份有限公司董事会 2025 年 4 月 30 日 ...

Financial Performance - The company reported a significant operating loss due to a decline in overall revenue, primarily impacted by market competition, business model adjustments, and a decrease in order volume [4]. - The company's operating revenue for 2024 was ¥690,765,562.41, a decrease of 31.33% compared to ¥1,005,929,309.42 in 2023 [24]. - The net profit attributable to shareholders for 2024 was -¥501,509,765.24, showing an improvement of 42.64% from -¥874,349,214.78 in 2023 [24]. - The net cash flow from operating activities was -¥35,682,984.51, a decline of 402.72% compared to ¥11,787,364.46 in 2023 [24]. - The total assets at the end of 2024 were ¥2,189,795,268.31, down 15.53% from ¥2,592,337,624.35 at the end of 2023 [24]. - The company reported a basic earnings per share of -¥0.53 for 2024, improving by 50.00% from -¥1.06 in 2023 [24]. - The company's revenue from core business activities, after deducting other income, was ¥635,589,837.98 in 2024, down from ¥792,024,301.02 in 2023 [24]. - The company reported a significant reduction in investment cash outflow by 48.50% to ¥612,186,484.88 from ¥1,188,616,583.06 [89]. - The company reported a total revenue of 16,946.37 million CNY, with a net profit loss of 33,558.94 million CNY for its subsidiary, Yihui Technology [117]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the fiscal year 2024, representing a growth of 20% year-over-year [196]. Strategic Initiatives - The company plans to not distribute cash dividends, issue bonus shares, or increase capital using reserves [7]. - The company launched the "思创物联（苍南）" production base, marking a strategic transformation and upgrade in its IoT application business [32]. - The company is transitioning from a manufacturer to a digital service provider, addressing industry challenges with comprehensive solutions [35]. - The company is actively developing a group hospital business collaboration and data sharing cloud platform in line with national healthcare reform initiatives, aiming to improve resource utilization and healthcare service quality [40]. - The company is investing in the development of personal digital health records, utilizing IoT, AI, and cloud computing technologies to enable dynamic aggregation and sharing of personal health data [41]. - The company is focusing on expanding its market presence and developing new technologies to enhance its product offerings [165]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million CNY earmarked for potential mergers and acquisitions [196]. - The company plans to increase its marketing budget by 30% to support the launch of new products and enhance brand visibility [197]. Market and Product Development - The company focuses on providing integrated solutions in sectors such as smart retail, supply chain management, and smart cities, leveraging RFID technology [32]. - The company is actively developing a smart retail management system and a smart supply chain platform to achieve full digitalization from inventory management to logistics [123]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024 [199]. - New product launches are expected to contribute an additional 300 million RMB in revenue in 2024, focusing on advanced medical technologies [199]. - The company is investing 200 million RMB in R&D for new technologies aimed at improving healthcare solutions over the next two years [199]. Governance and Management - The company has established a fair and effective performance evaluation and incentive mechanism for senior management, combining basic salary with annual performance assessments [148]. - The company has maintained independence from its largest shareholder, with no interference in decision-making or operational activities reported during the period [154]. - The company has implemented a robust internal control system to manage risks and ensure the normal operation of business activities [151]. - The company has established a comprehensive internal audit system, with an independent internal audit department reporting directly to the audit committee [151]. - The company has seen a turnover in key management positions, which may impact its operational strategy moving forward [168]. - The company appointed Wu Qiong as the new General Manager on May 28, 2024, following the resignation of Hua Songyuan due to work adjustments [167]. Challenges and Risks - The company continues to face challenges in its smart healthcare segment, with slow project delivery and payment collection contributing to operational losses [4]. - The company faces intensified competition in the IoT and smart healthcare sectors, requiring improved core competitiveness and cost structure optimization [128]. - The company is facing litigation risks from investors, with 18 lawsuits currently filed against it [136]. - The company is monitoring international trade policies and exchange rate fluctuations to manage potential risks in its business operations [133]. Research and Development - The company has received 14 invention patents, 14 utility model patents, and 23 software copyrights during the reporting period, showcasing its commitment to innovation [62]. - The company is investing heavily in R&D, with a budget allocation of 200 million CNY for new technologies and product development [196]. - Research and development expenditures have increased by 20%, reflecting the company's commitment to innovation [165]. - The company has initiated a cost-reduction strategy projected to save 100 million RMB annually, enhancing overall profitability [199]. International Operations - The company exports its products to over 70 countries and regions, establishing long-term stable partnerships with more than 300 clients and agents globally [50]. - International sales accounted for 52.02% of total revenue, down 24.20% from the previous year [72]. - The company is planning to expand its overseas market presence through localized solutions for smart loss prevention and digital retail technologies [123]. Financial Management - The company has engaged in foreign exchange hedging to mitigate risks associated with currency fluctuations, aiming to reduce the impact on operational performance [102]. - The company has implemented risk control measures for foreign exchange hedging, including monitoring and aligning hedging contracts with expected cash flows [103]. - The company has not engaged in speculative derivative investments during the reporting period [104]. - The company has established a unified data management platform for IoT data collection and analysis, achieving a 60% completion rate in user data processing [87].

Financial Performance - The company's revenue for Q1 2025 reached ¥409,267,469.05, representing a 105.78% increase compared to ¥198,888,851.70 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥19,559,000.77, an improvement of 71.14% from a loss of ¥67,764,977.31 in the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥29,473,021.51, which is a 56.91% improvement from a loss of ¥68,404,999.56 year-over-year[5] - The weighted average return on equity improved to -3.45% from -7.81% year-over-year, reflecting better financial performance[5] - The net profit for the current period was -19,436,112.60, compared to -68,576,893.20 in the previous period, indicating an improvement[28] - Total comprehensive income for the current period was -24,150,857.83, compared to -68,984,875.95 in the previous period[29] - Basic and diluted earnings per share were both -0.02, an improvement from -0.07 in the previous period[29] Assets and Liabilities - The company's total assets decreased by 31.19% to ¥1,506,875,539.19 from ¥2,189,795,268.31 at the end of the previous year[5] - Total liabilities decreased to ¥941,673,340.52 from ¥1,600,932,000.91, a reduction of about 41.2%[25] - Cash and cash equivalents increased to ¥439,934,835.34 from ¥415,200,644.88, reflecting a growth of approximately 5.5%[23] - Accounts receivable decreased to ¥353,033,883.16 from ¥395,319,679.02, a reduction of about 10.7%[24] - The company reported a cash and cash equivalents balance of 364,501,022.89 at the end of the period, down from 482,439,364.81 in the previous period[32] Cash Flow - The cash flow from operating activities was ¥25,805,801.61, showing a slight increase of 1.13% compared to ¥25,518,697.95 in the same period last year[5] - Operating cash flow net amount was 25,805,801.61, slightly up from 25,518,697.95 in the previous period[32] - Cash inflow from operating activities totaled 256,886,487.62, an increase from 227,704,641.50 in the previous period[31] - Cash outflow from operating activities was 231,080,686.01, compared to 202,185,943.55 in the previous period[32] - Investment activities generated a net cash flow of 725,351,084.89, significantly higher than 169,699,667.33 in the previous period[32] Shareholder Information - The total number of common shareholders at the end of the reporting period is 73,798[10] - The largest shareholder, Cangnan Siga IoT Smart Partnership, holds 5.72% of shares, totaling 63,890,185 shares[10] - The first major shareholder changed from Yunhai Chain Holdings to Mr. Lu Nan and his concerted actor, Hangzhou Botai Investment Management[17] - The total number of shares held by the top 10 shareholders does not include shares lent through margin trading[11] - The top 10 shareholders include both domestic and foreign entities, with significant stakes held by natural persons and corporations[10] Investment and Expenses - Research and development expenses decreased by 45.88% to ¥17,324,427.07 from ¥32,012,601.95 in the same period last year, attributed to organizational adjustments[8] - The company plans to invest up to RMB 50 million in Zhejiang Mashang Technology Co., with a subscription price of RMB 3.50 per share[18] Asset Disposal and Gains - The company recorded a substantial increase in asset disposal gains of 13,057.24%, amounting to ¥7,794,790.23 compared to a loss of ¥60,157.81 in the previous year[8] - The company sold assets for a total of RMB 562 million, with payments received of RMB 40 million and RMB 372 million as the first installment[15] - The second installment of RMB 115 million has been received as part of the asset sale[16] Legal and Guarantees - The company received a guarantee deposit of ¥58 million from the former chairman to cover potential liabilities related to a lawsuit[21] - The company expects no financial loss from the alleged guarantee issue, as the former chairman has committed to cover any excess liabilities[21] Strategic Initiatives - The company is actively pursuing new strategies for market expansion and product development, although specific details were not disclosed in the call[20]

Core Viewpoint - The sale of 100% equity in Yihui Technology by Sichuang Medical to Shanhai Digital for approximately 299.6 million RMB marks a strategic shift for Sichuang Medical, allowing it to divest from its underperforming smart healthcare business and focus on the commercial intelligence sector [1][2]. Group 1: Company Strategy - The primary objective of the transaction is to concentrate resources and funding on the commercial intelligence business, which is expected to optimize the company's business structure and promote high-quality development [1][2]. - After the sale, Yihui Technology will no longer be included in the consolidated financial statements, which is anticipated to improve the company's financial condition and performance metrics [1][3]. - The commercial intelligence business is based on EAS and RFID research and production, providing deep IoT solutions across various industries, with a strong market position in both EAS and RFID sectors [2]. Group 2: Financial Impact - In the period from January to October 2024, Yihui Technology reported revenues of 111 million RMB and a net loss of 316 million RMB, significantly dragging down the overall performance of Sichuang Medical [1]. - The divestiture is expected to enhance asset quality and profitability, as well as increase working capital reserves, thereby supporting the company's focus on commercial intelligence [1][2]. Group 3: Market Position and Future Outlook - The strategic support from state-owned enterprises is crucial for the development of the smart healthcare sector, highlighting the importance of national strategic technology forces [2]. - The transaction is viewed as a positive move that will not compromise the integrity of the company's operations but rather enhance profitability and long-term shareholder value [3].

北京德恒（杭州）律师事务所 关于 思创医惠科技股份有限公司 重大资产出售暨关联交易的 法律意见 杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 电话：0571-86508080 传真：0571-87357755 邮编：310016 | 一、 | 本次交易的方案 | 6 | | --- | --- | --- | | 二、 | 交易双方的主体资格 | 9 | | 三、 | 本次交易的批准和授权 | 22 | | 四、 | 本次交易涉及的相关协议 | 23 | | 五、 | 本次交易的标的资产 | 24 | | 六、 | 本次交易涉及的关联交易及同业竞争 66 | | | 七、 | 本次交易涉及的债权债务处理和人员安置 69 | | | 八、 | 本次交易的信息披露 | 69 | | 九、 | 本次交易的实质条件 | 70 | | 十、 | 参与本次交易的证券服务机构及其资格 73 | | | 十一、 | 本次交易相关人员买卖证券行为核查 74 | | | 十二、 | 结论意见 | 75 | 北京德恒（杭州）律师事务所 关于思创医惠科技股份有限公司 重大资产出售暨关联交易的法律意见 释义 在本《法 ...

国金证券股份有限公司 关于本次交易产业政策和交易类型的核查意见 思创医惠科技股份有限公司（以下简称"上市公司"）拟向苍南县山海数字 科技有限公司出售上市公司持有的医惠科技有限公司（以下简称"标的公司"） 100%股权，根据《上市公司重大资产重组管理办法》规定，上述交易事项构成 重大资产重组（以下简称"本次交易"或"本次重组"）。国金证券股份有限公 司（以下简称"本独立财务顾问"）担任本次交易的独立财务顾问。 根据中国证券监督管理委员会（以下简称"中国证监会"）《监管规则适用 指引——上市类第 1 号》、深圳证券交易所《深圳证券交易所上市公司自律监管 指引第 8 号——重大资产重组（2025 年修订）》等规范性文件的要求，本独立 财务顾问对上市公司本次交易的产业政策和交易类型进行了核查，核查意见如下： 一、本次交易涉及的行业与企业不属于《国务院关于促进企业兼并重组的 意见》和工信部等十二部委《关于加快推进重点行业企业兼并重组的指导意见》 确定的"汽车、钢铁、水泥、船舶、电解铝、稀土、电子信息、医药、农业产 业化龙头企业"；也不属于中国证监会《监管规则适用指引——上市类第 1 号》 确定的"汽车、钢铁、水泥、船舶 ...

目 录 | 一、审阅报告…………………………………………………………… | 第 | 1 页 | | --- | --- | --- | | 二、备考合并财务报表………………………………………………第 | 2—3 | 页 | | （一）备考合并资产负债表………………………………………… | 第 | 2 页 | | （二）备考合并利润表……………………………………………… | 第 | 3 页 | | ………………………………………第 4—82 页 | | --- | | 三、备考合并财务报表附注 | 审 阅 报 告 天健审〔2025〕8743 号 思创医惠科技股份有限公司全体股东： 我们审阅了后附的思创医惠科技股份有限公司（以下简称思创医惠公司）按 照备考合并财务报表附注三所述编制基础编制的备考合并财务报表，包括 2023 年 12 月 31 日和 2024 年 10 月 31 日的备考合并资产负债表，2023 年度和 2024 年 1-10 月的备考合并利润表以及备考合并财务报表附注。备考合并财务报表的 编制是思创医惠公司管理层的责任，我们的责任是在实施审阅工作的基础上对备 考合并财务报表出具审阅报告。 我们按 ...